OpenDNA provides an AI‑driven testing platform that generates multiple polygenic risk scores from a single blood sample, integrating these scores with clinical data to deliver comprehensive disease risk assessments across cardiovascular, cancer, autoimmune, neurodegenerative, mental health, respiratory, women’s health, and ocular conditions. The results are presented through an interactive, EMR‑integrated dashboard that offers real‑time decision support and scenario modeling, enabling clinicians to identify high‑risk patients early and personalize preventive care.
Funding
Funding not disclosed
Founders
Product
Problem
Clinicians lack integrated genomic risk information in routine practice, making early detection and personalized prevention of cardiometabolic diseases, cancer, and other complex conditions difficult and fragmented.
Solution
OpenDNA offers a single, AI‑driven testing platform that combines polygenic risk scores with clinical data to generate comprehensive risk assessments for multiple disease areas from one blood sample. The platform delivers disease‑specific scores for cardiovascular, cancer, autoimmune, neurodegenerative, mental health, respiratory, women’s health, and ocular conditions, as well as combined polygenic‑monogenic cancer analysis. Results are delivered through an interactive software interface that pulls patient data from electronic medical records, provides real‑time decision support, and enables “what‑if” scenario modeling for personalized prevention plans. By integrating these insights into existing workflows, clinicians can identify high‑risk individuals earlier, tailor screening and lifestyle interventions, and improve population health management.
Target Audience
Primary customers are primary care physicians, specialists (cardiologists, oncologists, genetic counselors), preventive health clinics, and health systems seeking AI‑enhanced genomic risk profiling for their patients.
Features
- AI‑powered algorithm that merges polygenic risk scores with patient clinical data for each disease indication
- Single laboratory test that generates multiple disease risk scores, including CardioRisk+, CancerRisk+, TotalRisk+ (polygenic‑monogenic), and PolyRisk+ (30+ conditions across eight categories)
- Seamless EMR integration for automated data pull and real‑time, interactive decision support dashboards
- Interactive patient‑engagement tools that allow clinicians to explore risk scenarios and personalize prevention recommendations
- Comprehensive cancer assessment combining monogenic panel (29 genes) with polygenic scoring for breast, colon, and prostate cancer
- Broad disease coverage spanning cardiovascular, cancer, autoimmune, neurodegenerative, mental health, respiratory, women’s health, and eye disorders